Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma скачать в хорошем качестве

Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma

Dr Talal El Zarif speaks to ecancer at ASCO GU 2023 about an international study from the Global Society of Rare Genitourinary Tumors which looks at the safety and efficacy of immune checkpoint inhibitors (ICIs) in advanced penile squamous cell carcinoma. He explains that the society reached out to 24 institutions and collected baseline data on overall survival, progression free survival and response rate. Dr El Zarif reports that the median overall survival was 9.8 months, the median progression free survival was 3.2 months and the overall response rate was 13%. In conclusion, the largest retrospective cohort of immune checkpoint inhibitor-treated advanced PeCa, ICIs showed no new safety signals, however, overall anti-tumour activity was limited. Dr El Zarif notes that future translational studies are needed to identify patients that are more likely to derive clinical benefit from ICIs. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php